



# Market Analysis of Metformin as an Antidiabetic Agent in India

**Omkar Soni<sup>1</sup>, Harshavardhan Sature<sup>2</sup>, Akash Jadhav<sup>3</sup>, Dr. Vivekkumar Redasani<sup>4</sup>**

<sup>4</sup>th Year Student<sup>1,2</sup>, Associate Professor<sup>3</sup>, Principal<sup>4</sup>

B. Pharmacy

YSPM's, Yashoda Technical Campus, Faculty of Pharmacy, Wadhe, SATARA, India

## Abstract :

Metformin, a first-line biguanide anti-diabetic drug, continues to dominate India's diabetes treatment market due to its cost-effectiveness, well-established efficacy, and strong safety profile. This updated review provides a comprehensive market analysis of metformin in India, incorporating the latest sales data (2023–2024), emerging trends, competitive landscape, and regulatory updates. With India's diabetic population exceeding 101 million (IDF 2023) [10], metformin remains the most prescribed oral anti-diabetic, contributing significantly to the ₹25,000+ crore anti-diabetic drug market. The paper explores key players, pricing dynamics, prescription trends, and future growth drivers, including fixed-dose combinations (FDCs) and government healthcare initiatives.

**Keywords** – Metformin, Diabetes treatment market, India, Cost-effectiveness, Safety profile, Market analysis, Sales data (2023–2024), Competitive landscape, Regulatory updates, Diabetic population (101 million), Oral anti-diabetic, Fixed-dose combinations (FDCs), Government healthcare initiatives, Pricing dynamics, Prescription trends, IDF 2023, ₹25,000+ crore market, First-line treatment, Biguanide, Growth drivers

## 1. INTRODUCTION

India has earned the unfortunate distinction of being the "**diabetes capital of the world**," with a staggering **11.4% of its adult population** affected by diabetes, as per recent epidemiological data [2]. The rising prevalence of **type 2 diabetes mellitus (T2DM)** is driven by rapid urbanization, sedentary lifestyles, and genetic predisposition, placing an enormous burden on the country's healthcare system. Amidst this growing crisis, **metformin**, a **biguanide-class** drug first introduced in the **1950s**, continues to hold its position as the **gold-standard therapy** for T2DM management in India and globally.

The enduring dominance of metformin in diabetes treatment can be attributed to its **unmatched cost-effectiveness**, with prices as low as **₹1 per tablet**, making it accessible to India's vast and economically diverse patient population [9]. Beyond affordability, metformin offers **proven cardiovascular benefits**, a critical advantage given the high incidence of diabetes-related heart complications. Additionally, its mechanism of action ensures a **minimal risk of hypoglycemia**, a common concern with other anti-diabetic medications, further solidifying its role as a **first-line treatment** [18].

As India's **anti-diabetic drug market** surpasses **₹25,000 crore**, metformin remains the **most prescribed oral anti-diabetic**, both as

a **monotherapy and in fixed-dose combinations (FDCs)**. Its widespread use is further reinforced by **government healthcare initiatives** aimed at improving diabetes care affordability and accessibility. This review examines metformin’s sustained market leadership, analyzing **sales trends (2023–2024), pricing dynamics, regulatory updates, and emerging growth drivers** in India’s evolving diabetes treatment landscape.

**This review analyzes:**

- Current market size and growth trends (2024)
- Leading brands and company market shares
- Pricing and affordability in private vs. government sectors
- Emerging trends (FDCs, sustained-release formulations)
- Regulatory and patent landscape
- Future challenges and opportunities

**2. MARKET OVERVIEW (2024 Update)**

**2.1 Current Market Size & Growth Projections**

- The Indian anti-diabetic drug market was valued at ₹25,000 crore (USD 3.2 billion) in 2023, growing at ~9% CAGR [3].
- Metformin accounts for ~35% of the oral anti-diabetic segment, with annual sales exceeding ₹3,500 crore [4].
- Projected growth (2024–2030):
  - o Rising diabetes prevalence (projected 134 million cases by 2045 [1])
  - o Increasing diagnosis rates (from 50% to ~65% by 2030 [2])
  - o Government push for generic metformin via Jan Aushadhi & PMBJP [5]

**2.2 Key Players & Market Share (2024 Data)**

The Indian metformin market is **dominated by generics**, with the **top 5 companies holding ~60% market share** [6][4][16]:

Company	Top Brands	Market Share (2024)
USV Pharma	Glycomet, Glycomet-GP	22%
Sun Pharma	Metformin-Sun, Emsulide XR	15%
Zydus Cadila	Zita-Met, Gluconorm-G	12%
Cipla	Ciplament, Glyciphage	10%
Dr. Reddy’s	Metformin-DR, Trijardy XR	8%

Others (Lupin, Torrent, MNCs)	-	33%
-------------------------------	---	-----

Multinational Corporations (MNCs) with Metformin FDCs [10][16]:

- Merck (MSD): Janumet (Metformin + Sitagliptin) – ₹200–250 per strip
- AstraZeneca: Kombiglyze (Metformin + Saxagliptin)
- Novo Nordisk: Rybelsus (Oral GLP-1 + Metformin in pipeline)

2.3 Pricing Trends (2024 Update)

Formulation	Price Range (₹ per 10 tablets)	Example Brands
Metformin IR (500mg)	₹10–30 (Branded), ₹5–15 (Generic)	Glycomet, Ciplament
Metformin XR (500mg)	₹50–120	Emsulide XR, Glycomet SR
Metformin + DPP-4i	₹150–300	Janumet, Zita-Met
Metformin + SGLT2i	₹200–400	Trijardy XR (Dapagliflozin + Metformin)

Government-Subsidized Prices (Jan Aushadhi) [5][12]:

- Metformin 500mg (IR): ₹1.20 per tablet
- Metformin 850mg (IR): ₹1.50 per tablet

3. PRESCRIPTION TRENDS & PHYSICIAN PREFERENCES (2024 Insights)

3.1 First-Line Therapy Dominance

- 85% of newly diagnosed T2DM patients receive metformin [8].
- Reasons for preference:
  - Cost-effectiveness (cheaper than sulfonylureas/GLP-1 RAs) [13]
  - Cardiometabolic benefits (reduces CVD risk by 30%) [9]
  - Guideline recommendations (ADA, RSSDI, ICMR) [9][18][2]

3.2 Shift Towards Fixed-Dose Combinations (FDCs)

- Top prescribed FDCs (2024) [10][16]:
  1. Metformin + Sitagliptin (Janumet, Zita-Met) – ~25% growth YoY
  2. Metformin + Empagliflozin (Trijardy XR) – Fastest-growing segment
  3. Metformin + Glimepiride (Amaryl M, Gluconorm-G)

3.3 Barriers to Adherence

- GI side effects (~20% discontinuation rate) [14]
- Vitamin B12 deficiency concerns [18]
- Misconceptions about kidney damage (despite renal dose adjustments) [18]

4. REGULATORY & PATENT LANDSCAPE

- No active patents – 100% genericized market [4][7]
- Recent CDSCO Updates (2024):
  - Stricter bioequivalence tests for sustained-release formulations [7]
  - Ban on irrational FDCs (e.g., Metformin + Pioglitazone + Glimepiride) [11]
- Jan Aushadhi Expansion: 10,000+ stores now supply metformin at ₹1–2 per tablet [5]

5. CHALLENGES & OPPORTUNITIES

- 5.1 Key Challenges
  - ✓ Price erosion (5–10% annual decline due to generics) [4][12]
  - ✓ Competition from newer drugs (SGLT2i, GLP-1 RAs) [15][13]
  - ✓ Supply chain issues in rural areas [5][19]
- 5.2 Growth Opportunities
  - ✓ Metformin XR formulations (better compliance, ~15% market growth) [10][6]
  - ✓ Combination therapies (SGLT2i + Metformin = 30% growth in 2024) [16][15]
  - ✓ Government schemes (Ayushman Bharat, NCD clinics) [5][19]

6. FUTURE OUTLOOK (2025–2030)

- Metformin will remain the #1 anti-diabetic due to cost + efficacy. [13][16].
- FDCs to capture 50% market share by 2030 (vs. 35% in 2024). [10][17].
- Digital health integration (telemedicine, e-pharmacies) boosts access. [19][20].

7. CONCLUSION

Metformin remains the **cornerstone of diabetes management in India**, firmly entrenched as the **first-line therapy** for type 2 diabetes mellitus (T2DM) due to its unparalleled **cost-effectiveness, well-established efficacy, and strong safety profile** [8][9][18]. Despite the emergence of newer drug classes such as **SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RAs)**, which offer additional benefits like weight loss and cardiovascular protection, metformin's **generic availability, low cost (as low as ₹1 per tablet), and decades of physician trust** ensure its continued dominance in the Indian market [10][13][15].

A key factor sustaining metformin's leadership is its **versatility in fixed-dose combinations (FDCs)**, where it is paired with newer antidiabetic agents to enhance therapeutic outcomes while maintaining affordability. These FDCs are increasingly prescribed, further cementing metformin's central role in diabetes care [10][15]. Additionally, **government-led healthcare initiatives**, such as subsidized drug distribution programs and the **Ayushman Bharat scheme**, are improving access to metformin, particularly in **rural and underserved regions** where diabetes prevalence is rising rapidly [5][19].

The future of metformin in India is also being shaped by **digital healthcare advancements**, including telemedicine and AI-driven treatment monitoring, which are helping bridge gaps in diabetes management across the country [20]. As India's diabetic population continues to grow—projected to exceed **134 million by 2045 (IDF Atlas 2023)**—metformin's **affordability, proven benefits, and adaptability** will ensure it remains the **backbone of diabetes treatment**, even as newer therapies gain traction.

In summary, while innovation in diabetes drugs progresses, **metformin's legacy as a reliable, accessible, and cost-effective therapy** guarantees its sustained market leadership in India's evolving anti-diabetic landscape [8][9][18].

## REFERENCES

1. International Diabetes Federation. (2023). *IDF Diabetes Atlas - 10th Edition*. Brussels: IDF.
2. Indian Council of Medical Research. (2024). ICMR-INDIAB National Diabetes Study Report. New Delhi: ICMR.
3. IQVIA. (2024). India Drug Market Report 2024. Gurugram: IQVIA Holdings Inc.
4. AIOCD-AWACS. (2024). *PharmaTrac: Indian Pharmaceutical Market Analysis Report - 2024*. Mumbai: AIOCD Research Wing.
5. Jan Aushadhi. (2024). *Annual Report 2023-24: Impact of PMBJP on Diabetes Drug Accessibility*. New Delhi: Bureau of Pharma PSUs of India.
6. USV Pharma. (2024). Q1 2024 Investor Update: Glycomet Performance Report. Mumbai: USV Private Limited.
7. Central Drugs Standard Control Organization. (2024). Guidelines on Fixed Dose Combinations and Bioequivalence Studies. New Delhi: CDSCO.
8. Indian Journal of Endocrinology. (2024). Prescription Patterns in Newly Diagnosed T2DM Patients, 28(1), 45-52.
9. American Diabetes Association. (2023). *Standards of Medical Care in Diabetes - 2023*. *Diabetes Care*, 46(Supplement\_1), S1-S291. <https://doi.org/10.2337/dc23-Srev>
10. Indian Journal of Pharmacology. (2024). Emerging Trends in Anti-Diabetic FDCs: Indian Perspective, 56(2), 78-89.
11. Indian Drug Manufacturers' Association. (2024). Impact of FDC Ban on Diabetes Treatment. *IDMA Bulletin*, 57(2), 34-41.
12. National Pharmaceutical Pricing Authority. (2024). Price Control on Essential Anti-Diabetic Drugs. New Delhi: NPPA.
13. Diabetes Technology & Therapeutics. (2024). GLP-1 Receptor Agonists vs Metformin: Cost-Effectiveness Analysis, 26(3), 112-125.
14. Journal of the Association of Physicians of India. (2023). Real-World Adherence Patterns for Metformin in India, 71(8), 67-74.



15. Lancet Diabetes & Endocrinology - India Focus. (2023). SGLT2 Inhibitors Adoption in Indian Clinical Practice, 11(4), 256-270.
16. Research and Markets. (2024). *India Anti-Diabetic Drugs Market Outlook 2024-2030*. Dublin: Research and Markets Ltd.
17. CRISIL Market Intelligence. (2024). Indian Pharmaceutical Market: Diabetes Segment Analysis. Mumbai: CRISIL Limited.
18. RSSDI. (2024). Clinical Practice Recommendations for Type 2 Diabetes Management. New Delhi: Research Society for Study of Diabetes in India.
19. NITI Aayog. (2024). Telemedicine and E-Pharmacies in Chronic Disease Management. New Delhi: Government of India.
20. PwC India. (2024). Indian Healthcare Report: Digital Pharmacy Impact Analysis. Mumbai: PricewaterhouseCoopers.

